Previous studies have also reported that alterations affecting IFNγ genes, including JAK1/2, STAT1/2, and IFNGR1, are rare (~5%), and although they have been identified in post-PD1 inhibitor progression melanoma samples9,16, these mutations have also been found in responding and non-responding melanoma patients8,40. This evidence concerns the gene STAT1 and melanoma.